A coagulant Weizmannella with high acetaldehyde dehydrogenase production and its application

Through the high-yield acetaldehyde dehydrogenase coagulated Weizmannia AlcoKer0031 and its composition, combined with plant extracts and auxiliary materials, it was prepared as a solid beverage for probiotic composition, which solved the problems of low alcohol metabolism efficiency and excessive liver burden. It achieves the effect of efficient alcohol relief and liver protection.

CN118773085BActive Publication Date: 2024-11-08中原食品实验室
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411259510.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08
Estimated Expiration
2044-09-10

AI Technical Summary

Technical Problem

The existing methods cannot effectively reduce the damage caused by alcohol to the human body. The effect of alcohol quenching and protecting the liver is not good, and the liver is overburdened after drinking. The lack of acetaldehyde dehydrogenase leads to low alcohol metabolism efficiency.

Method used

Provided with a high yield of acetaldehyde dehydrogenase, AlcoKer0031 and composition thereof, comprising plant extracts such as Pueraria root and Citrus extracts, supplemented with fructose oligosaccharide, maltodextrin and corn oligopeptide, Prepare a solid beverage for probiotic composition, and through fermentation and culture and emulsification of microcapsules, an efficient alcohol-relieving liver-protecting product is formed.

Benefits of technology

This composition can efficiently degrade alcohol, reduce the burden on the liver, significantly reduce the harm of alcohol to the human body, enhance the activity of acetaldehyde dehydrogenase, quickly decompose acetaldehyde, and protect liver health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118773085B_ABST
    Figure CN118773085B_ABST
Patent Text Reader

Abstract

The present invention discloses a coagulant Weizmannella with high acetaldehyde dehydrogenase production and its application. The classification of coagulant Weizmannella AlcoKer0031 is named ( Weizmannia coagulant ) , The preservation number is CGMCC NO. 31222. AlcoKer0031 and solid beverages containing AlcoKer0031 can efficiently degrade alcohol ingested by the human body, reduce the damage of alcohol to the liver, and maintain human health.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and particularly relates to Weizmannella coagulans with high acetaldehyde dehydrogenase production and application thereof. Background Art

[0002] Alcohol is an irritant drink that is toxic to the liver, kidneys, gastrointestinal tract, nervous system and circulatory system. Excessive drinking can lead to gastrointestinal disorders and induce gastric and duodenal ulcers. Acute drinking in large quantities may cause nausea, vomiting, memory loss, lack of concentration, impaired fine motor skills and emotional instability. In severe cases, it may even lead to respiratory muscle paralysis and death. Long-term excessive drinking may cause mental disorders, gastric ulcers and liver damage. In severe cases, people may suffer from fatty liver, alcoholic hepatitis and cirrhosis. Studies have shown that the increased incidence of esophageal cancer and liver cancer is related to drinking.

[0003] The human body eliminates ethanol mainly through metabolic pathways. A small amount of ethanol is excreted through breathing (0.7%), sweat (0.1%) and urine (0.3%). The rest of the ethanol is converted in the liver by alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH). The specific process is: ethanol enters the gastrointestinal tract through the mouth and esophagus, about 80% is absorbed in the stomach, about 18% is absorbed in the small intestine, and about 2% is excreted through breathing and sweat. After ethanol is absorbed into the blood, alcohol dehydrogenase converts it into acetaldehyde (its toxicity is 200 times that of ethanol), and then acetaldehyde dehydrogenase converts acetaldehyde into acetic acid, which is finally decomposed into carbon dioxide and water by other oxidases and excreted from the body. The number and activity of alcohol dehydrogenase and acetaldehyde dehydrogenase determine the metabolic efficiency of alcohol. Studies have shown that most people lack acetaldehyde dehydrogenase in their bodies, so their ability to sober up is weak.

[0004] In addition, excessive alcohol intake can cause the intestinal flora to lose balance, leading to gastrointestinal dysfunction, and may also promote the production of reactive oxygen molecules, pro-inflammatory cytokines, and chemokines, further damaging the liver. Currently, intestinal balance can be maintained by taking probiotics before drinking. However, this method takes a long time and cannot directly reduce the damage of alcohol to the human body, and the effect of sobering up and protecting the liver is not good. Summary of the invention

[0005] In order to solve the above technical problems, efficiently degrade excessive alcohol ingested by the human body, protect the liver, and reduce the harm of alcohol to the human body, the present invention provides the following technical solutions.

[0006] In the first aspect, the present invention provides a coagulant Weizmannella that produces high acetaldehyde dehydrogenase, wherein the coagulant Weizmannella AlcoKer0031 is classified as ( Weizmannia coagulans ) ,It is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with the deposit number CGMCC NO.31222 and the deposit date July 8, 2024.

[0007] In a second aspect, the present invention provides a composition, comprising the Weizmannella coagulans AlcoKer0031 described in the first aspect, which can efficiently decompose alcohol, thereby reducing the burden of excessive alcohol on the human liver and reducing the harm of alcohol to the human body.

[0008] Preferably, the composition further comprises a plant extract.

[0009] Furthermore, the plant extracts are kudzu root extract and Hovenia dulcis fruit extract, and the mass ratio of the kudzu root extract to the Hovenia dulcis fruit extract is 1-3:1-3, for example: 3:1, 2:1, 1:1, 1:2, 1:3.

[0010] Preferably, the composition further comprises an auxiliary material.

[0011] Furthermore, the auxiliary materials are composed of oligofructose, maltodextrin and corn oligopeptide;

[0012] More preferably, the mass ratio of the oligofructose, maltodextrin and corn oligopeptide is 2:2:1.

[0013] In a third aspect, the present invention provides a probiotic composition solid beverage, the solid beverage consisting of the following components:

[0014] 45-60 parts by weight of coagulated Weizmannella AlcoKer0031 microcapsules

[0015] 10-15 parts by weight of Pueraria root extract

[0016] Hovenia dulcis extract 10-15 parts by weight

[0017] 8-12 parts by weight of oligofructose

[0018] Maltodextrin 8-12 parts by weight

[0019] 3-8 parts by mass of corn oligopeptides.

[0020] Preferably, the solid beverage consists of the following components in mass fractions:

[0021] 50 parts by mass of coagulated Weizmannella AlcoKer0031 microcapsules

[0022] 12.5 parts by mass of Pueraria root extract

[0023] Hovenia dulcis extract 12.5 parts by mass

[0024] 10 parts by weight of oligofructose

[0025] Maltodextrin 10 parts by mass

[0026] 5 parts by mass of corn oligopeptides.

[0027] In a fourth aspect, the present invention provides a method for preparing the probiotic composition solid beverage according to the third aspect, the preparation method comprising the following steps:

[0028] S1, drying the kudzu root extract, the Hovenia dulcis extract, oligofructose, maltodextrin and corn oligopeptide until the water activity reaches a preset value, and then mixing the five raw materials to prepare a mixed material;

[0029] S2, fermenting and culturing Weizmannella coagulans AlcoKer0031, and freeze-drying the fermentation liquid to obtain a Weizmannella coagulans AlcoKer0031 starter culture;

[0030] S3, adding the coagulated Weizmannella AlcoKer0031 fermentation agent to the sodium alginate solution, stirring and mixing evenly, adding gelatin and calcium ion solution, emulsifying and freeze-drying to obtain coagulated Weizmannella AlcoKer0031 microcapsules;

[0031] S4, uniformly mixing the mixed material with the coagulant Weizmannella AlcoKer0031 microcapsules to prepare the liver-protecting and alcohol-resolving probiotic composition solid beverage.

[0032] Preferably, the drying method in S1 is low-temperature drying, and the preset value of water activity in S1 is ≤0.08, and more preferably ≤0.05.

[0033] Furthermore, the temperature of the low-temperature drying is 35-50°C, more preferably 35-45°C, for example: 35°C, 38°C, 40°C, 43°C, 45°C.

[0034] Furthermore, the low-temperature drying time is 1 to 5 h, more preferably 1 to 4 h, for example: 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h.

[0035] Preferably, the concentration of live bacteria in the coagulated Weizmannella AlcoKer0031 microcapsules in S3 is 1×10 9 ~9×10 11 CFU / g, for example: 1×10 9 CFU / g, 5×10 9 CFU / g, 7×10 9 CFU / g, 9×10 9 CFU / g, 1×10 10 CFU / g, 5×1010 CFU / g, 7×10 10 CFU / g, 9×10 10 CFU / g, 1×10 11 CFU / g, 5×10 11 CFU / g, 7×10 11 CFU / g, 9×10 11 CFU / g.

[0036] In a fifth aspect, the present invention provides a method for preparing a plant extract, the steps of the preparation method comprising:

[0037] S1, the plant extract sample is crushed, then mixed with ethanol, treated in an ultrasonic water bath, and then filtered to obtain the first filtrate.

[0038] S2, mixing the filter residue with ethanol, filtering after ultrasonic water bath to obtain the second filtrate.

[0039] S3, combining the two filtrates, removing the ethanol by rotary evaporation, and freeze-drying to obtain the plant extract.

[0040] Preferably, the mass ratio of the plant extract sample to ethanol is 1:8-15, for example: 1:8, 1:10, 1:12, 1:15.

[0041] The concentration of the ethanol is ≥70%, for example: 70%, 75%, 80%, 85%, 90%, 95%, 100%.

[0042] In a sixth aspect, the present invention provides use of the Weizmannella coagulans AlcoKer0031 described in the first aspect, the composition described in the second aspect, or the solid beverage described in the third aspect in the preparation of a product having an auxiliary protective effect on chemical liver damage.

[0043] Preferably, the chemical liver injury is caused by alcohol.

[0044] Beneficial effects of the present invention:

[0045] The coagulant Weizmannella AlcoKer0031 of the present invention can produce highly active acetaldehyde dehydrogenase. The coagulant Weizmannella AlcoKer0031 and a solid beverage containing the strain can efficiently degrade alcohol ingested by the human body, reduce the damage of alcohol to the liver, and maintain the health of the human body. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 The acetaldehyde content in the serum of mice in Example 4 is shown;

[0047] Figure 2 Shown is the acetaldehyde dehydrogenase content in mouse serum in Example 4

[0048] Figure 3 Shown is the superoxide dismutase content in the mouse serum in Example 4;

[0049] Figure 4 Shown is the alanine aminotransferase content in the serum of mice in Example 5;

[0050] Figure 5 The figure shows the aspartate aminotransferase content in the serum of mice in Example 5.

[0051] Culture deposits for patent procedures:

[0052] The coagulant Weizmannella AlcoKer0031 of the present invention;

[0053] Deposit date: July 8, 2024;

[0054] Depository: China General Microbiology Center (CGMCC);

[0055] Address of the depository: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, China, Postal Code: 100101;

[0056] Deposit number: CGMCC No. 31222;

[0057] Classification name: Weizmannella coagulans ( Weizmannia coagulans ). DETAILED DESCRIPTION

[0058] The technical solution of the present invention is further described below in conjunction with the embodiments and drawings, and the advantages and features of the present invention will become clearer with the description. However, it should be understood that the embodiments are only exemplary and do not limit the scope of the present invention.

[0059] It should be noted that the experimental methods used in the following examples are all conventional methods in the art unless otherwise specified. Unless otherwise defined, all scientific and technical terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention relates.

[0060] Example 1 Screening and domestication of Weizmannella coagulans

[0061] 1.1 Strain Isolation

[0062] The bacterial flora was isolated from commercially available kimchi. The specific isolation process was as follows:

[0063] (1) Pipette 2 mL of kimchi juice sample into 100 mL of MRS medium and culture at 37℃ for 16-22 h for enrichment.

[0064] (2) Gradient dilution: Pipette 0.5 mL of the enriched sample into 4.5 mL of sterile saline to obtain 10 -1 diluent, then pipette 0.5 mL 10 -1 Dilute in 4.5 mL saline to obtain 10 -2 Dilution, follow this procedure to obtain 10 -3 , 10 -4 , 10 -5 diluent.

[0065] (3) Plate culture: Pipette 100 μL of gradient dilution solution and plate it on MRS agar plate for 10 -3 , 10 -4 , 10 -5 One plate per gradient was cultured at 37°C for 48 h.

[0066] (4) Streak separation: Select colonies with typical characteristics on the coated plate based on their shape, size, edge, transparency, etc. Use an inoculation loop to pick up colonies and streak them on the selective culture medium plate. Incubate at 37°C for 48 h.

[0067] (5) Obtain a purified single colony, pick a single colony and inoculate it into 5 mL of MRS medium and culture it for 16-22 hours. At the same time, number each strain and perform strain domestication.

[0068] (6) Stress culture: The selected strains were inoculated into liquid MRS medium and 60% (v / v) acetaldehyde solution was added in a gradient manner for initial acclimatization. After each acclimatization culture in liquid medium for 18 h, they were acclimatized again in the same solid medium for 36 h. The acetaldehyde concentration in the culture medium is shown in Table 1.

[0069] Table 1 Acetaldehyde concentration in culture medium

[0070]

[0071] (7) After the initial acclimation, select strains with good growth and continue acclimation in the following acetaldehyde gradient medium culture medium: 18 h in liquid medium and 36 h in solid medium.

[0072] Table 2 Gradient concentration of acetaldehyde in culture medium

[0073]

[0074] (8) After the gradient acclimation, strains with excellent growth were selected for high-concentration acetaldehyde acclimation, cultured in liquid medium for 18 h and in solid medium for 36 h.

[0075] Table 3 High concentration acetaldehyde culture medium

[0076]

[0077] 1.2 Strain screening

[0078] Strains that grew well on high-concentration acetaldehyde plates were selected for continuous activation culture, and four strains with better growth were selected and numbered SL-06, SL-17, AlcoKer0031, and SL-23 for gastrointestinal tolerance experiments.

[0079] Each single strain was activated for three generations (18 h each time) before the experiment. The OD value of the strain activated for three generations at A600nm wavelength was measured, and the amount of bacterial solution required for OD600nm=5 was calculated.

[0080] Take the required bacterial solution and centrifuge it at 8000×g for 10 min, discard the supernatant, resuspend it in 1 mL of simulated gastric fluid, and culture it at 37℃ for 2.5 h before counting the live bacteria on the plate.

[0081] The required bacterial solution was centrifuged at 8000×g for 10 min, the supernatant was discarded, and the solution was resuspended in an equal volume of simulated intestinal fluid. After incubation at 37°C for 4 h, the live bacteria were counted on the plate.

[0082] The bacterial solution treated with simulated gastric fluid was centrifuged at 8000×g for 10 min, the supernatant was discarded, and the solution was resuspended in an equal volume of simulated intestinal fluid. After incubation at 37°C for 5 h, the live bacteria were counted on the plate.

[0083] The survival rate after tolerance to gastric juice (%) = (the number of live bacteria in the bacterial solution after tolerance to simulated gastric juice / the original number of live bacteria in the bacterial solution) × 100%.

[0084] The survival rate after tolerance to intestinal fluid (%) = (the number of live bacteria in the bacterial solution after tolerance to simulated intestinal fluid / the number of live bacteria in the bacterial solution after tolerance to simulated gastric fluid) × 100%.

[0085] The survival rate after tolerance to gastrointestinal fluid (%) = (the number of live bacteria in the bacterial solution after tolerance to simulated gastrointestinal fluid / the original number of live bacteria in the bacterial solution) × 100%.

[0086] Table 4 Gastrointestinal fluid tolerance of strains

[0087]

[0088] Note: Compared with SL-17, * indicates significant difference (p < 0.05), ** indicates extremely significant difference (p < 0.01).

[0089] 1.3 Strain identification

[0090] A single bacterial strain numbered AlcoKer0031 with the best gastrointestinal tolerance was selected, DNA was extracted, and 16SrRNA gene was amplified by PCR using universal primers 27F and 1492R. The obtained PCR product was sent to Meige Gene Sequencing Co., Ltd. for sequencing. The sequencing result was Condensation Weizmannia. The specific sequence is as follows:

[0091] 27F: 5'-AGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO. 1)

[0092] 1492R: 5'-GGTTACCTTGTTACGACTT-3' (SEQ ID NO.2)

[0093] 16S rRNA gene of AlcoKer0031 (SEQ ID NO.3):

[0094]

[0095] 1.3 Morphological characteristics of Weizmannella coagulans AlcoKer0031

[0096] Morphological identification of Weizmannella coagulans AlcoKer0031 showed the following characteristics:

[0097] (1) Morphological characteristics: The cells are rod-shaped, with a width of about 0.2 to 1.2 μm and a length of 1.2 to 3.5 μm. The cells are rod-shaped, Gram-positive, with terminal spores, no flagella, and are single, paired, or a few in short chains.

[0098] (2) Culture characteristics: The colonies on MRS solid medium are round or irregular in shape, generally white, and most of them have smooth surfaces;

[0099] (3) Physiological and biochemical characteristics: It can utilize glucose, lactose, arabinose, maltose, fructose, galactose, mannose, xylose, and sucrose; it does not reduce nitrate, and is negative for both catalase and oxidase; it has excellent ability to survive in a simulated gastrointestinal tract.

[0100] Example 2 Preparation of a solid beverage containing Weizmannella coagulans AlcoKer0031 as a probiotic composition for alcohol sobering and liver protection

[0101] Specification: 4g / pack. Formula see Table 5

[0102] Table 5: Formula of solid beverage of probiotic composition for hangover relief and liver protection

[0103]

[0104] The specific preparation process is as follows:

[0105] (1) Preparation of plant extracts: After pulverizing Pueraria root and Hovenia dulcis, 10 times the mass of 75% ethanol was added according to the mass ratio, and the mixture was ultrasonically treated in a water bath at 20-40 kHz and 50-60°C for 2-3 h, and then filtered to obtain the first filtrate; then 5 times the mass of 75% ethanol was added to the residue, and the mixture was ultrasonically treated in a water bath for 1 h, and then filtered to obtain the second filtrate, which was mixed with the first filtrate and the ethanol was removed by rotary evaporation. The plant extract powder was obtained by freeze drying. The freeze drying conditions were as follows: freezing at -25°C for 8-12 h, cold trap temperature of -60°C to -80°C, vacuum degree of 50-150 Pa, and drying time of 20-24 h.

[0106] (2) Preparation of Weizmannella coagulans AlcoKer0031 microcapsules: Weizmannella coagulans AlcoKer0031 was inoculated into MRS medium for activation culture to obtain a seed solution; the seed solution was inoculated into an optimized culture medium (the culture medium formula is: yeast peptone 13.0 g / L, glucose 27.0 g / L, yeast extract 7.0 g / L, sodium acetate 2.5 g / L, magnesium sulfate 0.13 g / L, Tween 80 0.65 g / L, oligomaltosaccharide 1.5 g / L, potassium dihydrogen phosphate 2.0 g / L. After dissolving the above ingredients, the pH was adjusted to 6.6) for fermentation culture to obtain a fermentation broth, which was freeze-dried to obtain a Weizmannella coagulans AlcoKer0031 starter. Sodium alginate was dissolved in water, and the coagulated Weizmannella AlcoKer0031 starter was added, stirred and mixed evenly, gelatin and calcium ion salt solution were added, emulsified, and then freeze-dried to obtain the coagulated Weizmannella AlcoKer0031 microcapsule particles (live bacteria concentration 5×10 10 CFU / g).

[0107] (3) Take 0.5 g of Pueraria root extract, 0.5 g of Hovenia dulcis extract, 0.4 g of oligofructose, 0.4 g of maltodextrin and 0.2 g of corn oligopeptide, and then test the water activity of the five raw materials respectively using a water activity meter;

[0108] (4) After the water activity test in step (3), 0.5 g of Pueraria root extract, 0.5 g of Hovenia dulcis extract, 0.4 g of oligofructose, 0.4 g of maltodextrin and 0.2 g of corn oligopeptide were placed in an oven, and then dried at a low temperature of 35-45°C with circulating air for 1-4 h;

[0109] (5) During this period, each raw material in the drying process of step (4) was taken out every 30 minutes, and then the water activity of 0.5 g of Pueraria extract, 0.5 g of Hovenia dulcis extract, 0.4 g of oligofructose, 0.4 g of maltodextrin and 0.2 g of corn oligopeptide was tested again using a water activity meter.

[0110] (6) According to the methods of step (4) and step (5), the Pueraria root extract, the Hovenia dulcis extract, the oligofructose, the maltodextrin and the corn oligopeptide are repeatedly dried and tested for water activity, and finally the water activity of each raw material is controlled below 0.05.

[0111] (7) The kudzu root extract with a water activity of less than 0.05 obtained in step (6), the Hovenia dulcis extract, oligofructose, maltodextrin and corn oligopeptide are placed in a blender, and then stirred at a speed of 200 rpm for 3 min to fully mix the raw materials to obtain a mixed material.

[0112] (8) Take the coagulated Weizmannella AlcoKer0031 microcapsules (live bacteria concentration 5×10 10 CFU / g), added to the mixture obtained in step (7), and then continued to stir at a speed of 200 rpm for 2 min to ensure that the probiotic powder, plant extract and auxiliary materials are evenly mixed to obtain a probiotic composition solid beverage.

[0113] Example 3 Test of ALDH Metabolism Ability of Weizmannella coagulans AlcoKer0031 in Vitro

[0114] The Weizmannella coagulans AlcoKer0031 screened in Example 1, common Weizmannella coagulans, common Lactobacillus plantarum, and Escherichia coli were inoculated into MRS liquid culture medium (added with 3% acetaldehyde, v / v), cultured at 37°C for 16 h, and then centrifuged at 8000 rpm to obtain the cells. The cells were washed with PBS buffer and then resuspended in fermentation broth. After low-temperature ultrasonic disruption, the supernatant was centrifuged at 4000 rpm to obtain the supernatant. The acetaldehyde dehydrogenase (ALDH) activity was determined by ELISA. The results are shown in Table 6.

[0115] Table 6 ALDH enzyme activity of different strains

[0116]

[0117] Compared with the control group, * indicates a significant difference (p < 0.05), and ** indicates an extremely significant difference (p < 0.01).

[0118] The results of enzyme activity test showed that the acetaldehyde dehydrogenase activity was from high to low, in the order of AlcoKer0031 strain, common Lactobacillus plantarum, common Weizmannella coagulans, and Escherichia coli, and the difference between AlcoKer0031 strain and Escherichia coli reached a very significant level; while there was no significant difference between common Lactobacillus plantarum and common Weizmannella coagulans, but there was a significant difference between AlcoKer0031 strain and Escherichia coli. The acetaldehyde dehydrogenase activity of AlcoKer0031 strain was 7.6 times that of common Weizmannella coagulans, and the difference between the two was very significant.

[0119] Example 4 Effect of Weizmannella coagulans AlcoKer0031 on acetaldehyde dehydrogenase and superoxide dismutase in mice

[0120] Twenty SPF mice were randomly selected and divided into a blank control group and an AlcoKer0031 group, with 10 mice in each group, half male and half female. All mice were gavaged with 7 mL / kg body weight of 53° liquor 30 min before the experiment. The AlcoKer0031 group was given 2 g of the solid beverage in Example 2, and the blank control group was given 2 g of normal saline. Blood was collected from the tails of the mice at 0.5 h, 1.5 h, and 3 h after taking the blood, and the ELISA kit was used to determine the levels of acetaldehyde (AC), acetaldehyde dehydrogenase (ALDH), and superoxide dismutase (SOD) in the serum. The experimental results are shown in Figure 1-Figure 3 .

[0121] like Figure 1 As shown, compared with the blank control group, 3 hours after taking the solid beverage, the acetaldehyde content in the serum of mice in the AlcoKer0031 group was significantly decreased (p < 0.05), reducing the damage of acetaldehyde converted from ethanol to mouse liver cells.

[0122] like Figure 2 As shown, compared with the blank control group, within 1.5 hours after taking the solid beverage, the acetaldehyde dehydrogenase content in the serum of mice in the AlcoKer0031 group increased significantly (p < 0.05), which can quickly decompose acetaldehyde in a short period of time and reduce the damage of alcohol to mouse liver cells.

[0123] like Figure 3 As shown, compared with the blank control group, within 1.5 hours after taking the solid beverage, the superoxide dismutase content in the serum of mice in the AlcoKer0031 group increased rapidly, eliminating residual free radicals in a shorter time and reducing alcohol damage to the liver.

[0124] Figure 1-Figure 3 The results show that solid beverages containing AlcoKer0031 have obvious alcohol sobering and liver protecting effects.

[0125] Example 5 Effect of Weizmannella coagulans AlcoKer0031 on alcohol dehydrogenase, alanine aminotransferase and aspartate aminotransferase in mice

[0126] Thirty SPF male mice were randomly selected, and after 7 days of adaptive feeding, they were divided into a group of 10 mice. They were randomly divided into a blank group, a model group, and an AlcoKer0031 group. The mice in the model group and the blank group were gavaged with 10 mL / kg of pure water, and the AlcoKer0031 group was fed with 2 g of the solid beverage in Example 2 every day for 30 consecutive days. 4 hours after the last administration, the blank group was given 10 mL / kg of normal saline, and the other groups were given the same volume of 10 mL / kg 56° liquor. After 1 hour, blood was collected from the tail of the mice, and serum was obtained by centrifugation. ELISA kits were used to measure the levels of alcohol dehydrogenase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in the serum. The results are shown in Table 7. Figure 4 , Figure 5 .

[0127] Table 7 ADH content in mouse serum

[0128]

[0129] Compared with the model group, * indicates significant difference (p < 0.05).

[0130] As can be seen from Table 7, compared with 2.48 U / mL ADH in the model group, the ADH content in the AlcoKer0031 group was 4.09 U / mL, an increase of 65%, and the difference between the two groups reached a significant level (p < 0.05). This shows that Weizmannella coagulans AlcoKer0031 can significantly promote ethanol metabolism.

[0131] like Figure 4 and Figure 5 As shown, compared with the model group mice, the ALT and AST levels of the AlcoKer0031 group mice were significantly reduced, indicating that Weizmannella coagulans AlcoKer0031 has a good protective effect on mouse liver cells and alleviates the damage of alcohol to stem cells.

[0132] Table 7 Figure 4 and Figure 5 The results show that solid beverages containing AlcoKer0031 have obvious alcohol sobering and liver protecting effects.

[0133] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

Claims

1. A coagulant Weizmannella that produces high acetaldehyde dehydrogenase, characterized in that: The coagulant Weizmannella Weizmannia coagulans )AlcoKer0031 is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with the deposit number CGMCC NO.31222 and the deposit date July 8, 2024.

2. A composition, characterized in that: The composition comprises the Weizmannella coagulans of claim 1 .

3. The composition according to claim 2, characterized in that: The composition further comprises a plant extract, wherein the plant extract is a kudzu root extract and a Hovenia dulcis fruit extract, and the mass ratio of the kudzu root extract to the Hovenia dulcis fruit extract is 1-3:1-3; The plant extract is prepared according to the following method: After pulverizing Pueraria root and Hovenia dulcis respectively, 10 times the mass of 75% ethanol were added according to the mass ratio, and the mixture was ultrasonically treated in a water bath at 20-40 KHZ and 50-60°C for 2-3 h, and then filtered to obtain the first filtrate; then 5 times the mass of 75% ethanol was added to the filter residue again, and the mixture was ultrasonically treated in a water bath for 1 h, and then filtered to obtain the second filtrate, which was mixed with the first filtrate and the ethanol was removed by rotary evaporation, and the plant extract powder was obtained by freeze-drying. The freeze-drying conditions were as follows: freezing at -25°C for 8-12 h, cold trap temperature at -60°C to -80°C, vacuum degree at 50-150 Pa, and drying time at 20-24 h.

4. The composition according to claim 2, characterized in that: The composition further comprises auxiliary materials consisting of oligofructose, maltodextrin and corn oligopeptide, and the mass ratio of the oligofructose, maltodextrin and corn oligopeptide is 2:2:

1.

5. A probiotic composition solid beverage, characterized in that: The solid beverage consists of the following components: 45-60 parts by weight of coagulated Weizmannella AlcoKer0031 microcapsules; 10-15 parts by weight of kudzu root extract; 10-15 parts by weight of Hovenia dulcis fruit extract; 8-12 parts by weight of oligofructose; 8-12 parts by weight of maltodextrin; 3-8 parts by weight of corn oligopeptide; The Weizmannella coagulans AlcoKer0031 is the Weizmannella coagulans in claim 1, and the Pueraria root extract and the Hovenia dulcis fruit extract are the Pueraria root extract and the Hovenia dulcis fruit extract in claim 3.

6. A method for preparing the probiotic composition solid beverage according to claim 5, characterized in that: The preparation method comprises the following steps: S1, drying the kudzu root extract, the Hovenia dulcis extract, oligofructose, maltodextrin and corn oligopeptide respectively until the water activity reaches a preset value, and then mixing the five raw materials to prepare a mixed material; S2, fermenting and culturing Weizmannella coagulans AlcoKer0031, and freeze-drying the fermentation liquid to obtain a Weizmannella coagulans AlcoKer0031 starter culture; S3, adding the coagulated Weizmannella AlcoKer0031 fermentation agent to the sodium alginate solution, stirring and mixing evenly, adding gelatin and calcium ion solution, emulsifying and freeze-drying to obtain coagulated Weizmannella AlcoKer0031 microcapsules; S4, uniformly mixing the mixed material with the coagulated Weizmannella AlcoKer0031 microcapsules to prepare the probiotic composition solid beverage.

7. The preparation method according to claim 6, characterized in that: The drying method in step S1 is low temperature drying, and the preset value of water activity in step S1 is ≤0.

08.

8. The preparation method according to claim 6, characterized in that: The concentration of live bacteria in the coagulated Weizmannella AlcoKer0031 microcapsules in step S3 is ≥10 10 CFU / g.

9. Use of the Weizmannella coagulans AlcoKer0031 according to claim 1, the composition according to any one of claims 2 to 4, or the solid beverage according to claim 5 in preparing a product having an auxiliary protective effect on alcoholic liver damage.

Citation Information

Patent Citations

  • Witzmann bacillus capable of inhibiting activity of alpha-glucosidase and / or alpha-amylase and application of Witzmann bacillus

    CN115322931A

  • Application of Witzia coagulans IOB502 staged fermentation microbial inoculum in alcoholic liver injury

    CN117511825A

  • Pet probiotics and preparation method thereof

    CN117752014A

  • Weizmannia coagulans capable of inhibiting activity of alpha-glucosidase and / or alpha-amylase and use thereof

    WO2024037588A1